Quantcast

Eli Lilly and Company Expands Authorized Generic Agreements with Prasco®

April 1, 2014

- Prasco to market the Authorized Generic of EVISTA® in the United States

CINCINNATI, April 1, 2014 /PRNewswire/ — Prasco Laboratories, announced today it has signed a marketing and distribution agreement with Eli Lilly and Company (NYSE: LLY) to market the Authorized Generic (AG) version of EVISTA(®) (raloxifene hydrochloride tablets), in 60 mg strength in the United States. Prasco will begin shipping the product immediately. The financial terms of the agreement were not disclosed.

“Prasco continues to demonstrate our passion to bring high-quality, low-cost prescription drugs to consumers,” said Prasco president and chief operating officer, David Vucurevich, R.Ph. “EVISTA represents our third Eli Lilly and Company Authorized Generic product launched, and we are very pleased to broaden that relationship.

“Prasco’s Authorized Generic products ensure consistent supply to customers and pharmacists. Additionally, our AG products allow patients to continue their therapy using the same brand with which they are accustomed, but at a generic cost savings,” Vucurevich concluded.

EVISTA(®) is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women; Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis; Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. Important Limitations: EVISTA is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer.

    You should not take
     EVISTA if you have
     had or are at risk
     for getting blood
     clots in the legs,
     lungs or eyes, as it
     may increase the risk
     of blood clots. Stop
     taking EVISTA and
     call your doctor if
     you have leg pain or
     warmth, swelling of
     the legs, hands or
     feet, chest pain,
     shortness of breath
     or a sudden vision
     change, as these may
     be signs of a blood
     clot. Being unable to
     move around for long
     periods may increase
     this risk. If you
     will need to be still
     for a long time, talk
     to your doctor about
     ways to reduce the
     risk of blood clots.

    EVISTA does not
     increase the risk of
     a heart attack or
     stroke in women who
     have had or are at
     risk for a heart
     attack; however;
     EVISTA increases the
     likelihood of dying
     from stroke in these
     women, should one
     occur. Before taking
     EVISTA tell your
     doctor if you have
     had a stroke, a mini-
     stroke, irregular
     heartbeat, high blood
     pressure, heart
     attack, history of
     smoking, or believe
     you have other risk
     factors for stroke or
     a heart attack.
    ----------------------

For additional information about EVISTA, please see Full Prescribing Information and Medication Guide at http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020815s018lbl.pdf.

About Prasco Laboratories - Prasco, the Authorized Generic Company, is the privately held healthcare company located in Mason, Ohio. The leader in Authorized Generics, Prasco has more AG partnerships than any other company. Established brand companies rely on Prasco to bring their brand products to the generic marketplace as Authorized Generics, which offers alternatives to consumers and pharmacists. For more information, visit www.prasco.com.

RALX-1007

SOURCE Prasco Laboratories


Source: PR Newswire



comments powered by Disqus